These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6219902)

  • 1. Tolerance and efficacy of erythromycin stearate tablets versus enteric-coated erythromycin base capsules in the treatment of patients with acne vulgaris.
    Bleeker J
    J Int Med Res; 1983; 11(1):38-41. PubMed ID: 6219902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bioavailability of erythromycin stearate versus enteric-coated erythromycin base when taken immediately before and after food.
    Clayton D; Leslie A
    J Int Med Res; 1981; 9(6):470-7. PubMed ID: 7319133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study.
    Gammon WR; Meyer C; Lantis S; Shenefelt P; Reizner G; Cripps DJ
    J Am Acad Dermatol; 1986 Feb; 14(2 Pt 1):183-6. PubMed ID: 2936772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal side effects with erythromycin preparations.
    Carter BL; Woodhead JC; Cole KJ; Milavetz G
    Drug Intell Clin Pharm; 1987 Sep; 21(9):734-8. PubMed ID: 3498618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption of erythromycin stearate and enteric-coated erythromycin base after a single oral dose immediately before breakfast.
    Schreiner A; Digranes A
    Infection; 1984; 12(5):345-8. PubMed ID: 6511088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparison of patient tolerance to enteric-coated vs nonenteric-coated erythromycin.
    Ellsworth AJ; Christensen DB; Volpone-McMahon MT
    J Fam Pract; 1990 Sep; 31(3):265-70. PubMed ID: 2202773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of systemic erythromycin stearate on the inflammatory lesions and skin surface fatty acids in acne vulgaris.
    Bleeker J; Hellgren L; Vincent J
    Dermatologica; 1981; 162(5):342-9. PubMed ID: 6454598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris.
    Marazzi P; Boorman GC; Donald AE; Davies HD
    J Dermatolog Treat; 2002 Sep; 13(3):111-7. PubMed ID: 12227873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of study design in assessing food effects on absorption of erythromycin base and erythromycin stearate.
    DiSanto AR; Chodos DJ
    Antimicrob Agents Chemother; 1981 Aug; 20(2):190-6. PubMed ID: 7283417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative bioavailability evaluation of erythromycin base and its salts and esters. I. Erythromycin estolate capsules versus enteric-coated erythromycin base tablets.
    DiSanto AR; Tserng KY; Chodos DJ; DeSante KA; Albert KS; Wagner JG
    J Clin Pharmacol; 1980 Jul; 20(7):437-43. PubMed ID: 7430412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two oral forms of erythromycin in the treatment of acute respiratory tract infections. A multicentre general practice study.
    Macklin J; Barden R; Coles S
    J Int Med Res; 1989; 17(3):287-94. PubMed ID: 2670633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of a new erythromycin solution for acne vulgaris.
    Rivkin L; Rapaport M
    Cutis; 1980 May; 25(5):552-5. PubMed ID: 6445816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythromycin 2 percent gel in the treatment of acne vulgaris.
    Pochi PE; Bagatell FK; Ellis CN; Stoughton RB; Whitmore CG; Saatjian GD; Sefton J
    Cutis; 1988 Feb; 41(2):132-6. PubMed ID: 2964344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of respiratory tract infections with erythromycin acistrate and two formulations of erythromycin base.
    Wuolijoki E; Flygare U; Hildén M; Hurme J; Järvinen H; Leskinen J; Pynnönen S; Riikonen A; Salomaa V; Seuri M
    J Antimicrob Chemother; 1988 Jun; 21 Suppl D():107-12. PubMed ID: 3391872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and bacteriological evaluation of tetracycline and erythromycin in acne vulgaris.
    Al-Mishari MA
    Clin Ther; 1987; 9(3):273-80. PubMed ID: 2955899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythromycin tolerance.
    Hahn DL
    J Fam Pract; 1990 Dec; 31(6):668-70. PubMed ID: 2246643
    [No Abstract]   [Full Text] [Related]  

  • 17. Relative bioavailability of enteric coated pellets, stearate and ethylsuccinate formulations of erythromycin.
    Tjandramaga TB; Van Hecken A; Mullie A; Verbesselt R; De Schepper PJ; Verbist L; Josefsson K
    Pharmacology; 1984; 29(6):305-11. PubMed ID: 6334320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia.
    Anderson G; Esmonde TS; Coles S; Macklin J; Carnegie C
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():117-24. PubMed ID: 1827098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerance of enteric-coated erythromycin base (Ery-Max) administered twice or four times daily in patients with acute bronchitis.
    Pekkanen PS; Josefsson K
    J Int Med Res; 1983; 11(5):285-8. PubMed ID: 6642069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A topical azithromycin preparation for the treatment of acne vulgaris and rosacea.
    McHugh RC; Rice A; Sangha ND; McCarty MA; Utterback R; Rohrback JM; Osborne BE; Fleischer AB; Feldman SR
    J Dermatolog Treat; 2004 Sep; 15(5):295-302. PubMed ID: 15370397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.